rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

BioPharma Terug naar discussie overzicht

GTCB - GTC Biotherapeutics - Deel 12

2.690 Posts
Pagina: «« 1 2 3 4 5 6 ... 135 »» | Laatste | Omlaag ↓
  1. [verwijderd] 30 oktober 2008 15:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Tja als de economie stagneert dan gaan de zwakste er uit
    dat is duidelijk
    lol

    quote:

    psycho-pharma schreef:

    Wish, ik denk dat het topbedrijf waar hij werkt (geld, transacties, advisering) hem even niet nodig heeft daar in het oosten, zodat hij ons weer komt teisteren.
    En nu maar hopen, dat de economie weer aantrekt, dan heeft hij weer werk.

    P.
  2. [verwijderd] 31 oktober 2008 09:43

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    COX zegt: we live in challenging times...........

    slappe hap natuurlijk, daar zou een bio-bedrijf helemaal geen last van moeten heben.

    maar cfo Green is niet in staat geweest om zijn huishoudboekje op orde te hebben.

    immers het geld is bijna op. ( zeg december )

    Jas heeft gelijk, hij is erg negatief maar realist,

    want al de zaken die hij noemt worden door ons niet gepareerd met steekhoudende argumenten.

    het schelden maakt ons zwak, en dat is onze positie, dat is de positie van gtcb.

    want hoe gaan ze de togo financieren.

    A: is het netjes om je steekhouders zo lang in het ongewisse te laten omtrent de continuiteit van je bedrijf die duidelijk in de gevarenzone verkeert.

    B: men heeft geen keus omdat men geen oplossing heeft dus blijft het stil.

    overname dan door Ovation zou de redding betekenen

    die overname zie ik dan ook als enige alternatief van de huidige challenging times waarin COX beweert te leven.

    mvg, iemand?
  4. [verwijderd] 31 oktober 2008 19:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    France
    De soep word nooit zo heet gegeten als die opgediend word

    Wij hadden het ook allemaal liever anders gezien
    Ik denk dat GTCB voorwaardelijk over is

    Dus ik blijf positief

    www.nasdaq.com/asp/holdings.asp?symbo...

    Groet,

    quote:

    france schreef:

    geen kip,....tok.....ja 1

    mvg, 38
  5. [verwijderd] 1 november 2008 12:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Die William Harris zit er lange tijd in en moet hebben gekocht op 1.70 usd met de emmissie toedertijd. Had ook nog wat warrants ontvang die hij kan omzetten indien de koers 2.20 usd is. Dus wie weet stuuwt WH nog eens de koers omhoog.
  6. [verwijderd] 2 november 2008 11:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zo te zien hebben ze SkySpam1 eindelijk geblokt, heeft lang gekost maar het is zo ver blijkbaar, al is het lekker rustig nu....toch had het voor mij niet gehoeven,maar wel terecht natuurlijk.
  7. [verwijderd] 2 november 2008 18:25

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dan hebben ze een verkeerde geblokt
    goede info de juiste opstelling enz voorts


    quote:

    d-investor schreef:

    Zo te zien hebben ze SkySpam1 eindelijk geblokt, heeft lang gekost maar het is zo ver blijkbaar, al is het lekker rustig nu....toch had het voor mij niet gehoeven,maar wel terecht natuurlijk.
  9. [verwijderd] 3 november 2008 13:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    GTC SIGNS AGREEMENT FOR $15 MILLION CONVERTIBLE DEBT FINANCING FROM LFB /FINANCING SUBJECT TO SHAREHOLDER APPROVAL



    FRAMINGHAM, MA – November 3, 2008 – GTC Biotherapeutics, Inc.’s ("GTC", Nasdaq: GTCB) signed an agreement with LFB Biotechnologies, its collaboration partner for a number of recombinant plasma protein and monoclonal antibody development programs, for a $15 million financing in which GTC will issue convertible debt and warrants to purchase shares of GTCB common stock. The financing, which will be for GTC’s corporate purposes across all programs, is subject to approval by GTC shareholders, consent by GE Capital and other closing conditions. It is scheduled for a stockholder vote and closing in mid-December 2008. GTCexpects net proceeds at closing, after transaction costs and establishment of a restricted cash account, to be approximately $10 million.



    Under the agreement, the convertible debt will mature on June 30, 2012,and will bear interest at an annual rate of 8%. The debt may be converted into GTC common stock at $0.31 per share at LFB’s discretion at any time after June 1, 2009. GTC has the right to redeem the debt on or before June 1, 2009. GTC will also issue to LFB 5-year warrants to purchase approximately 23.2 million shares of GTCB common stock at $0.31 per share. If the debt is repaid in full, LFB will have the right to require GTC to redeem the warrants for an aggregate price of $1.5 million. As a condition of the financing, $4 million of the proceeds will be placed in a restricted cash account to secure GTC’s existing debt to GE Capital.



    “Our collaborative relationship with LFB is one of GTC’s most important strategic relationships as we navigate these difficult financial markets,” stated Geoffrey F. Cox, Ph.D., GTC’s CEO and Chairman of the Board. “This financing will enable GTC to complete the significant regulatory and partnering milestones for ATryn® in the US in the first quarter of 2009. In addition, we will continue to pursue our overall strategy of developing collaborative strategic partnerships across the full range of our development pipeline.”



    The convertible debt will be secured by a first lien on GTC’s intellectual property and a second lien on all of GTC’s other assets except for the restricted cash account for GE Capital. In addition, the debt will be secured by a grant of rights and licenses with respect to certain products, including GTC’s co-exclusive rights under its collaboration agreement with LFB. The convertible debt will be subordinated to the current term debt with GE Capital.



    The LFB financing is subject to a vote of GTC shareholders and completion of an intercreditor agreement between LFB and GE Capital.



    About GTC Biotherapeutics

    GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. ATryn®, GTC’s recombinant human antithrombin, has been approved for use in Europe and has begun the review process in the United States under a Biologics License Application. In addition to ATryn®, GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa, VIII, and IX, which are used for the treatment of hemophilia, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 and a monoclonal antibody to CD137. GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC’s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, www.gtc-bio.com.



    IMPORTANT INFORMATION

    GTC intends to file a proxy statement and other relevant documents with the Securities and Exchange Commission (the "SEC") in connection with seeking the necessary shareholder approvals to complete the financing discussed above. GTC shareholders should read the proxy statement and other relevant documents when they become available because they will contain important information about the financing and the related proposals. The proxy statement, any amendments or supplements to the proxy statement, and other relevant documents filed by GTC with the SEC will be available free of charge at the SEC’s website, www.sec.gov, and at the GTC’s website, www.gtc-bio.com. Copies of these documents will also be available free of charge by submitting a written request to GTC Biotherapeutics, Inc., 175 Crossing Boulevard, Framingham, MA 01702, ATTN: Investor Relations. GTC, its directors and certain of its executive officers may be deemed participants in the solicitation of proxies from GTC’s shareholders with respect to the proposals related to the financing. Information about GTC’s directors and executive officers and their respective interests in the financing will be set forth in the proxy statement that GTC will file with the SEC in connection with seeking the necessary shareholder approvals to complete the financing. Additional information regarding GTC’s directors and executive officers is also included in GTC’s definitive proxy statement for its 2008 annual meeting, which was filed with the SEC on May 21, 2008, and is available by the means described above.

  10. [verwijderd] 3 november 2008 13:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    CapraVacca schreef:

    Belangrijk dagje morgen ik hoop dat er iets goed in het vat zit wat de financiële positie zeker stelt tot ruim in 2009.

    Grtz CV

    PRESS RELEASE: GTC Signs Agreement for $15 Million Convertible Debt Financing From LFB
    PRESS RELEASE: GTC Signs Agreement for $15 Million Convertible Debt Financing From LFB

    Financing Subject to Shareholder Approval
    FRAMINGHAM, Mass.--(BUSINESS WIRE)--November 03, 2008--

    GTC Biotherapeutics, Inc.´s ("GTC", Nasdaq: GTCB) signed an agreement with LFB Biotechnologies, its collaboration partner for a number of recombinant plasma protein and monoclonal antibody development programs, for a $15 million financing in which GTC will issue convertible debt and warrants to purchase shares of GTCB common stock. The financing, which will be for GTC´s corporate purposes across all programs, is subject to approval by GTC shareholders, consent by GE Capital and other closing conditions. It is scheduled for a stockholder vote and closing in mid-December 2008. GTC expects net proceeds at closing, after transaction costs and establishment of a restricted cash account, to be approximately $10 million.



    Under the agreement, the convertible debt will mature on June 30, 2012, and will bear interest at an annual rate of 8%. The debt may be converted into GTC common stock at $0.31 per share at LFB´s discretion at any time after June 1, 2009. GTC has the right to redeem the debt on or before June 1, 2009. GTC will also issue to LFB 5-year warrants to purchase approximately 23.2 million shares of GTCB common stock at $0.31 per share. If the debt is repaid in full, LFB will have the right to require GTC to redeem the warrants for an aggregate price of $1.5 million. As a condition of the financing, $4 million of the proceeds will be placed in a restricted cash account to secure GTC´s existing debt to GE Capital.



    "Our collaborative relationship with LFB is one of GTC´s most important strategic relationships as we navigate these difficult financial markets," stated Geoffrey F. Cox, Ph.D., GTC´s CEO and Chairman of the Board. "This financing will enable GTC to complete the significant regulatory and partnering milestones for ATryn(R) in the US in the first quarter of 2009. In addition, we will continue to pursue our overall strategy of developing collaborative strategic partnerships across the full range of our development pipeline."



    The convertible debt will be secured by a first lien on GTC´s intellectual property and a second lien on all of GTC´s other assets except for the restricted cash account for GE Capital. In addition, the debt will be secured by a grant of rights and licenses with respect to certain products, including GTC´s co-exclusive rights under its collaboration agreement with LFB. The convertible debt will be subordinated to the current term debt with GE Capital.



    The LFB financing is subject to a vote of GTC shareholders and completion of an intercreditor agreement between LFB and GE Capital.


    About GTC Biotherapeutics


    GTC Biotherapeutics develops, supplies, and commercializes therapeutic proteins produced through transgenic animal technology. ATryn(R), GTC´s recombinant human antithrombin, has been approved for use in Europe and has begun the review process in the United States under a Biologics License Application. In addition to ATryn(R), GTC is developing a portfolio of recombinant human plasma proteins with known therapeutic properties. These proteins include recombinant forms of human coagulation factors VIIa, VIII, and IX, which are used for the treatment of hemophilia, and alpha-1 antitrypsin. GTC also has a monoclonal antibody portfolio that includes a monoclonal antibody to CD20 and a monoclonal antibody to CD137. GTC´s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC´s transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as proteins that are required in large volumes. Additional information is available on the GTC web site, www.gtc-bio.com.


    IMPORTANT INFORMATION


    GTC intends to file a proxy statement and other relevant documents with the Securities and Exchange Commission (the "SEC") in connection with seeking the necessary shareholder approvals to complete the financing discussed above. GTC shareholders should read the proxy statement and other relevant documents when they become available because they will contain important information about the financing and the related proposals. The proxy statement, any amendments or supplements to the proxy statement, and other relevant documents filed by GTC with the SEC will be available free of charge at the SEC´s website, www.sec.gov, and at the GTC´s website, www.gtc-bio.com. Copies of these documents will also be available free of charge by submitting a written request to GTC Biotherapeutics, Inc., 175 Crossing Boulevard, Framingham, MA 01702, ATTN: Investor Relations. GTC, its directors and certain of its executive officers may be deemed participants in the solicitation of proxies from GTC´s shareholders with respect to the proposals related to the financing. Information about GTC´s directors and executive officers and their respective interests in the financing will be set forth in the proxy statement that GTC will file with the SEC in connection with seeking the necessary shareholder approvals to complete the financing. Additional information regarding GTC´s directors and executive officers is also included in GTC´s definitive proxy statement for its 2008 annual meeting, which was filed with the SEC on May 21, 2008, and is available by the means described above.


    Forward-Looking Statement


    This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding GTC´s ability to obtain shareholder approval of the financing or satisfy any of the other conditions to completing the financing, the timing of the financing, and the potential for further success in GTC´s continuing partnering strategy. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such statements. Factors that may cause such differences include, but are not limited to, the risks and uncertainties discussed in GTC´s most recent Annual Report on Form 10-K and its other periodic reports filed with the Securities and Exchange Commission, including the uncertainties associated with dependence upon the actions of partners and court authorities. GTC cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and GTC undertakes no obligation to update or revise the statements, except as may be required by law.


    CONTACT: GTC Biotherapeutics, Inc.
    Thomas E. Newberry, 508-370-5374
    Vice President, Corpora
  13. [verwijderd] 3 november 2008 13:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ben bang, ondanks het positieve nieuws dat er een beetje geld aankomt, dat de koers de komende dagen ergens tussen de $ 0,20 en $ 0,26 zal bivakkeren.
  14. [verwijderd] 3 november 2008 13:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    CapraVacca schreef:

    Belangrijk dagje morgen ik hoop dat er iets goed in het vat zit wat de financiële positie zeker stelt tot ruim in 2009.

    Grtz CV
    precies capra, de financiele positie, die moet worden veiliggesteld niet voor een paar maand maar voor liefst 1 jaar of beter 2 jaar, dat was nl. het beleid van gtcb voordat het moeilijk werd aan geld te komen.

    per jaar heeft men 20 miljoen nodig, dus kom nu niet aanzetten met een sukkelig lening kie van 5 of 7 miljoen want daar zitten de aandeelhouders natuurlijk niet op te wachten.

    die goedkeuring van DIC fase 2 van leo wordt verwacht in de 2e helft van volgend jaar,

    afronding van die fase gaat het nodige geld opleveren al wil gtcb niet zeggen hoeveel.

    als men daar niets over kwijt wil zal het te ontvangen bedrag wel tegenvallen, zeg 8 miljoen.

    menig bio-bedrijfje sluit gewoon een lening af a
    9.5% gtcb heb ik dat nog niet zien doen.

    nieuwe aandelen uitgeven tegen een koers van vandaag is ook geen optie, alleen als het de enige optie is.

    dan zal men niet direkt voor de volle mep gaan, immers Q2 dit jaar leverde een toename van de kaspositie op.

    gezegd is reeds dat de cash burn volgend jaar zal afnemen en ook het ingecalculeerde verlies voor de rest van 2008 zijnde 14 miljoen is hoog ingezet.

    kaspositie is nu nog 12 miljoen.

    wellicht dat ze kunnen lenen van partners, maar dat gaat natuurlijk ten koste van, ja van wat.

    het beste zou zijn overname, dan zijn we ervan af.

    overnameprijs? in ieder geval meer dan 1 dollar.

    vanmiddag 4 uur de conf. call.

    succes.
  16. [verwijderd] 3 november 2008 13:29

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    :)
    GTC Signs Agreement for $15 Million Convertible Debt Financing From LFB
    Monday November 3, 7:00 am ET
    Financing Subject to Shareholder Approval

    FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc.’s ("GTC", Nasdaq: GTCB) signed an agreement with LFB Biotechnologies, its collaboration partner for a number of recombinant plasma protein and monoclonal antibody development programs, for a $15 million financing in which GTC will issue convertible debt and warrants to purchase shares of GTCB common stock. The financing, which will be for GTC’s corporate purposes across all programs, is subject to approval by GTC shareholders, consent by GE Capital and other closing conditions. It is scheduled for a stockholder vote and closing in mid-December 2008. GTC expects net proceeds at closing, after transaction costs and establishment of a restricted cash account, to be approximately $10 million.

    Under the agreement, the convertible debt will mature on June 30, 2012, and will bear interest at an annual rate of 8%. The debt may be converted into GTC common stock at $0.31 per share at LFB’s discretion at any time after June 1, 2009. GTC has the right to redeem the debt on or before June 1, 2009. GTC will also issue to LFB 5-year warrants to purchase approximately 23.2 million shares of GTCB common stock at $0.31 per share. If the debt is repaid in full, LFB will have the right to require GTC to redeem the warrants for an aggregate price of $1.5 million. As a condition of the financing, $4 million of the proceeds will be placed in a restricted cash account to secure GTC’s existing debt to GE Capital.

    “Our collaborative relationship with LFB is one of GTC’s most important strategic relationships as we navigate these difficult financial markets,” stated Geoffrey F. Cox, Ph.D., GTC’s CEO and Chairman of the Board. “This financing will enable GTC to complete the significant regulatory and partnering milestones for ATryn® in the US in the first quarter of 2009. In addition, we will continue to pursue our overall strategy of developing collaborative strategic partnerships across the full range of our development pipeline.”

    The convertible debt will be secured by a first lien on GTC’s intellectual property and a second lien on all of GTC’s other assets except for the restricted cash account for GE Capital. In addition, the debt will be secured by a grant of rights and licenses with respect to certain products, including GTC’s co-exclusive rights under its collaboration agreement with LFB. The convertible debt will be subordinated to the current term debt with GE Capital.

    The LFB financing is subject to a vote of GTC shareholders and completion of an intercreditor agreement between LFB and GE Capital.

    IMPORTANT INFORMATION

    GTC intends to file a proxy statement and other relevant documents with the Securities and Exchange Commission (the "SEC") in connection with seeking the necessary shareholder approvals to complete the financing discussed above. GTC shareholders should read the proxy statement and other relevant documents when they become available because they will contain important information about the financing and the related proposals. The proxy statement, any amendments or supplements to the proxy statement, and other relevant documents filed by GTC with the SEC will be available free of charge at the SEC’s website, www.sec.gov, and at the GTC’s website, www.gtc-bio.com. Copies of these documents will also be available free of charge by submitting a written request to GTC Biotherapeutics, Inc., 175 Crossing Boulevard, Framingham, MA 01702, ATTN: Investor Relations. GTC, its directors and certain of its executive officers may be deemed participants in the solicitation of proxies from GTC’s shareholders with respect to the proposals related to the financing. Information about GTC’s directors and executive officers and their respective interests in the financing will be set forth in the proxy statement that GTC will file with the SEC in connection with seeking the necessary shareholder approvals to complete the financing. Additional information regarding GTC’s directors and executive officers is also included in GTC’s definitive proxy statement for its 2008 annual meeting, which was filed with the SEC on May 21, 2008, and is available by the means described abov
  17. [verwijderd] 3 november 2008 14:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GTC BIOTHERAPEUTICS REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS



    FRAMINGHAM, MA – November 3, 2008 -- GTC Biotherapeutics, Inc.’s ("GTC", Nasdaq: GTCB)total net loss for the third quarter ended September 28, 2008 was $6.1 million, or $0.06 per share, compared with $8.4 million, or $0.11 per share, in the third quarter of 2007. The total net loss for the first nine months of 2008 was $16.5 million, or $0.17 per share, compared to $26.5 million, or $0.34 per share, for the first nine months of 2007.



    “GTC has made great strides this quarter by completing the Biologics License Application, or BLA, for ATryn® and obtaining Priority Review designationin the United States,” stated Geoffrey F. Cox, Ph.D., GTC’s Chairman and Chief Executive Officer. “We recently entered into a partnership with OVATION Pharmaceuticals for the commercialization and development of ATryn® in the US. We are also taking action to transfer the ATryn® program from LEO Pharma to LFB Biotechnologies, already an important strategic partner of ours, to provide a positive impetus to commercial and clinical development of ATryn in Europe and the Middle East. These activities are all buttressed by today’s announcement of LFB’s commitment to lend us financial support, which provides the runway for us to meet significant milestones in the development of ATryn® in the US.”



    ATryn® Commercial and Clinical Progress

    ATryn®is GTC’s recombinant form of human antithrombin, a plasma protein with anticoagulant and anti-inflammatory properties. The collaboration agreement with OVATION Pharmaceuticals, Inc. includes $257 million in potential payments to GTC for meeting clinical, regulatory, and sales milestones, including a $3 million payment from OVATION to GTC that was made at the closing, $2 million in payments made for regulatory milestones in 2008, and up to an additional $4 million in milestone payments through a successful approval ofATryn®in 2009 for the hereditary antithrombin deficiency, or HD, indication. GTC has completed the BLA forATryn® to be reviewed for this indication by the US Food and Drug Administration, or FDA. The FDA has accepted the filing, granting GTC’s request for Priority Review and assigning an action date of February 7, 2009 with an advisory panel planned for January 2009. The FDA previously designated ATryn® as an Orphan Drug.



    GTC has entered into negotiations for the transition of the program for the commercialization and clinical development ofATryn® for Europe and the Middle East from LEO Pharma to LFB. This follows an internal strategic review and reprioritization by LEO. LEO has confirmed that there are no safety or efficacy issues with theATryn® product either commercially or in the Phase II clinical study for the potential treatment of disseminated intravascular coagulation, or DIC, associated with severe sepsis.



    LFB, currently a 20% shareholder in GTC, has expressed a significant interest in commercializingATryn® in Europe and the Middle East for its existing indications. LFB is also interested in continuing the development ofATryn® in the ongoing Phase II DIC study and for other clinical indications. Further patients are not being recruited into the Phase II study until completion of the transition to LFB. LFB has additional strategic commercialization and development programs with GTC in recombinant plasma proteins, including factor VIIa, factor IX and alpha-1 antitrypsin, and also an anti-CD20 monoclonal antibody.



    Cash Position

    Cash and marketable securities at September 28, 2008 totaled $8.8 million, a $7 million decrease compared to $15.8 million at December 30, 2007. GTC recently signed an agreement with LFB for $15 million of convertible debt financing. The convertible debt, which matures on June 30, 2012, will be subordinated to the current term debt with GE Capital, and will become convertible into GTC common stock at LFB’s option if the debt is not repaid by June 1, 2009. As a condition of the financing, $4 million of the proceeds will be placed in escrow to secure the existing debt to GE Capital. The financing, which is subject to approval by GTC shareholders, consent by GE Capital and other closing conditions, is scheduled to close in mid-December 2008.We expect net proceeds after transaction costs and the escrow amount to be approximately $10 million. With successful completion of the $15 million financing from LFB, GTC projects that its cash resources will be sufficient to support its operations into the second quarter of 2009.



    Other Financial Results

    Revenues were approximately $2.9 million for the current quarter, a $300,000 increase from approximately $2.6 million in the third quarter 2007. The revenues in the third quarter 2008 were primarily from the program with PharmAthene for the services provided for their Protexia® product and from the completion of the production program for Merrimack Pharmaceuticals for their MM-093 product. Third quarter revenues in 2007 were primarily from the services provided to PharmAthene and Merrimack. Revenues for the first nine months of 2008 totaled $15.6 million, a $4.8 million increase compared to the $10.8 million in the first nine months of 2007. The increase in revenues for the nine-month results were primarily due to the sale of ATryn® product to LEO as well as revenue derived from the PharmAthene program.



    Costs of revenue and operating expenses were $8.8 million in the current quarter, a 19% decrease from the $10.9 million in the third quarter 2007. Costs of revenue and operating expenses were $31.5 million in the first nine months of 2008, a 16% decrease from the $37.6 million in the first nine months of 2007. The decrease in the quarter and nine month costs were primarily due to lower costs in the ATryn® program and funding provided by LFB to offset GTC’s costs in the joint venture collaboration programs. These lower costs were partially offset by the increased activity to support the PharmAthene program. The decrease in expenses for the ATryn® program is primarily due to the higher costs in 2007 from the write-off of inventory that was rendered unusable as a result of a fill/finish process at a US-based contractor.



    The per share results were affected by an increase in the weighted average number of shares outstanding from 78 million shares in the third quarter 2007 to 102.9 million shares in the third quarter 2008. The weighted average number of shares outstanding increased from 77.8 million shares in the first nine months of 2007 to 96.6 million shares in the first nine months of 2008. The increases in the weighted average shares outstanding primarily reflect the issuance of shares of common stock in a registered direct offering in February 2008 and the conversion from preferred stock to common stock by LFB in March 2008. GTC had approximately 102.9 million common shares outstanding as of September 28, 2008.



    NASDAQ Staff has informed GTC that the date for meeting compliance with the minimum $1.00 bid price requirement for continued listing has been extended to April 20, 2009. This extension conforms to NASDAQ’s recently instituted policy to suspend action on the minimum bid price and market value rules between October 16, 2008 and January 16, 2009. GTCcan regain compliance, either during the suspension or during the compliance period resuming after the suspension, by achieving a $1 clo
  19. [verwijderd] 3 november 2008 15:18

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    beur schreef:

    Tjongejonge, wat een ontwikkelingen.... Dat moeten we allemaal nog eens goed laten bezinken.
    En nog steeds niemand hier die durft te gokken welke kant de koers straks opgaat..???
2.690 Posts
Pagina: «« 1 2 3 4 5 6 ... 135 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.124
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.212
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.865
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.846
Aedifica 3 926
Aegon 3.258 323.086
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.906
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.051
Alfen 16 25.301
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 423
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.953
AMG 971 134.440
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.034 320.998
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.623
ASML 1.766 110.302
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.958
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449